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Abstract
Background: Cytogenetic abnormalities are important prognostic markers in plasma cell myeloma (PCM) and
detection is routinely performed by interphase fluorescence in-situ hybridization (FISH) with a panel of probes
after enrichment of the plasma cells in the bone marrow specimen. Cell sorting by immunomagnetic beads
and concurrent labeling of the cytoplasmic immunoglobulin are the usual enrichment methods. We present
an alternative method of plasma cell enrichment termed Target FISH, which is an automated system that
combines the images of May-Grünwald- Giemsa (MGG) staining and FISH study on the same plasma cell
for analysis.
Results: Our experience of Target FISH on 40 PCM patients was described. Briefly, plasma cells were MGG
stained, image captured, de-stained, FISH probe hybridized and finally relocated for simultaneous analysis
of morphology and FISH signal pattern. The FISH probe panel was TP53/CEP17, t(4;14) IGH/FGFR3, t(14;16) IGH/
MAF and CKS1B(1q21)/CDKN2C(P18). Gain of 1q21 was the most common abnormality detected in 18 patients
(45 %), to be followed by t(4;14) IGH/FGFR3 detected in 11 patients (27.5 %). Of note, 10 patients showed
coexistence of both t(4;14) and 1q21 gain. Two patients showed del(17p)/TP53, one in association with t(4;14)
and 1q gain while the other was stand alone. None of this patient cohort showed t(14;16) IGH/MAF. Using
the critical binomial function, the normal cutoff FISH positive value for del(17p)/TP53 was 3.4 %, t(4;14) IGH/
FGFR3 was 6.8 %, t(14;16) IGH/MAF was 5.6 % and +1q21 was 5.7 %.
Conclusions: The equipment cost notwithstanding, when compared with cell sorting, the total reagent cost
was around 10 % lower in Target FISH. The total processing time was longer for Target FISH but manual
fluorescence microscopy was no longer necessary. The main advantage of Target FISH was the complete
certainty that the cytogenetic abnormality was detected in the cells of interest, and hence a more stringent
analytical cutoff value might be considered. Optimization of the cell collection and slide preparation process
upfront was required to accrue adequate target cells on each slide for analysis. Our experience suggested
that Target FISH was applicable as a routine method of plasma cell enrichment in clinical diagnostic
laboratories.
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Background
The detection of cytogenetic abnormalities in PCM is
clinically important as a prognostic marker to risk stratify
patients [1]. While conventional metaphase chromosome
study detects cytogenetic abnormalities in only one third
of PCM patients, interphase FISH improves the detection
frequency to around 90 % of patients [2]. The reasons for
the discrepancy are attributable to low plasma cell per-
centage in the bone marrow, low proliferative index of the
plasma cells and hence outgrown by granulocytic pre-
cursors, and that chromosome translocations such as
t(4;14)(p16;q32) may be morphologically cryptic or co-
exist with other complex changes and escape detection by
the less experienced cytogeneticist.
It is not recommended to perform interphase FISH
directly on the PCM bone marrow due to often low plasma
cell percentage and admixture by other hemopoietic cells.
The plasma cells should be selected either by immuno-
magnetic beads or flow cytometry based plasma cell sorting
or concurrent labeling of the cytoplasmic immunoglobulin
(cIg) light chain to allow unambiguous detection of cyto-
genetic abnormalities in the neoplastic plasma cell popula-
tion[3, 4]. The enrichment techniques of cell sorting [5] or
cIg-FISH [6] however are labor, time and cost intensive.
Hence the incorporation of these methods into the routine
workflow of a diagnostic cytogenetics laboratory may be
challenging. An alternative method of plasma cell enrich-
ment termed Target FISH based on sequential MGG stain
to identify plasma cell populations to be followed by FISH
analysis was previously reported [7]. Herein, we present an
automated Target FISH system for use in routine molecular
diagnostics.
Results and discussion
We reported the experience on the initial 40 PCM pa-
tients for whom Target FISH was performed (Table 1).
These patients were accrued in a 12-month period from
April 2015 to March 2016. The patients comprised 20
males and females each at a median age of 61 years (range
47–89 years). The median percentage of plasma cells in
the bone marrow was 29 % (range 12–100 %). Monoclonal
gammopathy of undetermined significance (MGUS) were
excluded. In the same time period, two samples in which
FISH was failed (due to heavy background fluorescence
and aged sample respectively) and one inadequate sample
were also excluded. Conventional cytogenetic study results
were available in only 10 patients (no. 2, 7, 9, 13, 17, 21,
22, 25, 33 and 35) for correlation (Table 1).
Gain of 1q21 was the most common abnormality de-
tected in 18 patients (45 %), which was consistent with
the high prevalence of this cytogenetic abnormality re-
ported in the literature [8–10]. The t(4;14) IGH/FGFR3
was detected in 11 patients (27.5 %). Of note, 10 patients
showed coexistence of both t(4;14) and 1q21 gain. Again
this observation was consistent with the much overlap
between adverse IgH translocations and 1q21 gain as
reported by the UK MRC Myeloma IX Trial [11]. Two
patients showed del(17p)/TP53, one in association with
t(4;14) and 1q gain while the other was stand alone.
None of this patient cohort showed t(14;16) IGH/MAF.
However 4 patients tested positive for t(11;14) IGH/
CCND1, which was performed selectively when the
myeloma cells showed small lymphoplasmacytic morph-
ology and expression of CD20 [12]. Incidental finding of
secondary abnormalities i.e. monosomy or deletion of
chromosomes 4, 14 or 16 or trisomy or amplification of
chromosomes 4, 14 or 16 detected by t(4;14) IGH/FGFR3
and/or t(14;16) IGH/MAF FISH probes were encountered
in 17 patients.
The normal cutoff value to define FISH positivity for
each probe was determined in the laboratory by studying
a cohort of 6 normal control samples together with the
negative results in the patient samples for the FISH
probes del(17p)/TP53 (n = 38), t(4;14) IGH/FGFR3 (n =
29), t(14;16) IGH/MAF (n = 40) and +1q21 (n = 22). The
6 normal controls were patients with reactive plasmacy-
tosis proven by absence of paraprotein and lack of light
chain restriction on the plasma cells. This normal con-
trol cohort consisted of 2 male patients and 4 female
patients with an age range of 41–81 years. The diagnoses
were metastatic colon cancer, adult Still’s disease, anaplas-
tic large cell lymphoma, incidental finding of increased
globulins on checkup, primary osseous diffuse large B-cell
lymphoma and primary hyperparathyroidism. The range
of bone marrow plasma cells was 6–8 %. The definition of
false positive signal pattern was less than 2 red signals for
TP53/CEP17, any yellow fusion signal for t(4;14) IGH/
FGFR3 or t(14;16) IGH/MAF, and more than 2 red signals
for chromosome 1q CKS1B/CDKN2C. The critical bino-
mial function of the Microsoft Excel spreadsheet was used
to determine the 95 % confidence limit of normal cutoff
value [13]. The normal cutoff value for TP53/CEP17 was
3.4 %, t(4;14) IGH/FGFR3 was 6.8 %, t(14;16) IGH/MAF
was 5.6 % and chromosome 1q CKS1B/CDKN2C was
5.7 %. However, for clinical reporting, conservative cutoff
levels of 10 % for fusions and 20 % for numerical abnor-
malities were generally recommended [4]. In the literature,
other cutoff values were quoted, for example 30 % for
chromosome 1q gain [14] and 60 % for del(17p) [15].
Notwithstanding the analytical validation, the clinical
significance of the cutoff value should also be considered.
For example, a study on bortezomib-based chemotherapy
in PCM patients according to the copy number of 1q21
showed that 20 % of involved plasma cells or more had no
significant difference on survival, indirectly confirming the
validity of 20 % rather than a higher cutoff in defining 1q
gain [16]. Similarly another FISH study showed that 50 %
for 17p deletion and 20 % for 1q gain were the optimal
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Table 1 Summary of Target FISH results on 40 patients
No. Sex/Age PC%a BioViewb Del(17p)/TP53 t(4;14) t(14;16) +1q21 Others
1 M/52 26 % 14–16 % (10323–15875) Neg (230)c 38 % + (74) Neg (201) 30 % + (180)
2 F/80 15 % 3–4 % (9605–13508) Neg (89) Neg (61) Neg (71) Neg (71) Normal cytogenetics
3 M/69 12 % 3–4 % (8880–11094) Neg (84) Neg (46)g Neg (40)g Neg (62)
4 M/81 43 % No record Neg (253) Neg (188) Neg (175) Neg (200) 5/9/15 60 % + (235)
5 M/64 15 % 58–64 % (11912–17007) Neg (159) Neg (153) Neg (156)g Neg (155) 5/9/15 Neg (84)
6 M/70 17 % 4–7 % (7132–7616) Neg (63) Neg (53)g Neg (51)g 80 % + (53) 5/9/15 Neg (61)
7 F/52 35 % 8–12 % (7750–8981) Neg (159) 90 % + (112)g Neg (102)g 65 % + (167) Cytogeneticsd: hypodiploid 78.5 %,
hyperdiploid 7 %, normal 14.5 %
8 F/72 13 % 42–55 % (11829–14627) Neg (32) Neg (35) Neg (71) Neg (54)
9 F/71 17 % 7–9 % (8667–11174) Neg (82) 70 % + (54) Neg (37) 50 % + (65) Normal cytogenetics
10 M/61 65 % 17–24 % (10289–13997) Neg (135) Neg (94)g Neg (98)g 90 % + (145)
11 M/54 15 % 15–22 % (12898–19268) Neg (141) 80 % + (87) Neg (84) Neg (113) 5/9/15 Neg (171)
12 M/47 100 % 50–59 % (10424–12419) 50 % + (132) Neg (144)g Neg (107)g Neg (156)
13 M/59 60 % 10–12 % (9514–13412) Neg (154) Neg (133)g Neg (128)g Neg (140) t(11;14) 90 %+; normal
cytogenetics
14 M/81 22 % 50–52 % (10110–15964) Neg (140) 60 % + (78)g Neg (111)g 85 % + (172) 5/9/15 Neg (101)
15 F/67 45 % 21–27 % (6066–7366) Neg (163) 90 % + (145) Neg (136) 85 % + (183) 5/9/15 Neg (157)
16 M/58 No record 8–9 % (6666–8923) Neg (250) Neg (192)g Neg (188)g Neg (224) t(11;14) 25 % + (228)
17 F/70 51 % 13–17 % (7469–8551) Neg (183) Neg (137)g Neg (118)g 85 % + (162) Normal cytogenetics
18 F/53 23 % 10 % (2719–4195) Neg (198) Neg (146) Neg (80) Neg (106) 5/9/15 Neg (87)
19 M/76 70 % 6–7 % (4145–5686) Neg (108) Neg (89) Neg (102) Neg (101) IgH Neg (71)
20 M/61 49 % 17–19 % (4210–5352) Neg (170) Neg (126) Neg (119) 85 % + (172)
21 M/61 20 % 24–29 % (9895–11736) Neg (145) Neg (122) Neg (87) Neg (142) Normal cytogenetics
22 F/48 59 % 6–9 % (6942–7583) 40 % + (172) 65 % + (110) Neg (111) 55 % + (154) Normal cytogenetics
23 F/56 100 % 3–8 % (4400–6203) Neg (123) Neg (149)g Neg (118) 65 % + (158)
24 F/55 84 % 3–6 % (9304–10362) Neg (141) Neg (148) Neg (107) Neg (82) t(11;14) 85 % + (121)
25 M/52 74 % 11–23 % (10024–12394) Neg (158) 85 % + (100) Neg (135)g 90 % + (162) Cytogeneticse: hypodiploid clone,
der(4)t(1;4)(q21;p16) and add(7p)
26 F/56 35 % 11–17 % (10247–12375) Neg (100) Neg (166) Neg (140)g Neg (117)
27 F/55 73 % 10–17 % (3419–5581) Neg (186) Neg (167) Neg (142) Neg (171)
28 F/57 15 % 6–8 % (5191–6330) Neg (102) Neg (122) Neg (102) Neg (100)
29 F/69 16 % 25–32 % (7923–12371) Neg (172) Neg (143)g Neg (104)g Neg (173)
30 M/58 19 % 3–5 % (6385–8924) Neg (213) Neg (169) Neg (154) Neg (208)
31 F/66 29 % 7–11 % (7383–9153) Neg (149) 70 % + (73) Neg (108)g 80 % + (127)
32 F/56 15 % 7–12 % (11256–13079) Neg (146) Neg (117)g Neg (93) Neg (150)
33 M/64 13 % 4–6 % (11082–12940) Neg (118) Neg (100) Neg (98) Neg (101) t(11;14) 40 % + (149);
cytogeneticsf: loss of
Y chromosome
34 F/67 21 % 6–13 % g11872–14598) Neg (159) 70 % + (104) Neg (118)g 95 % + (136)
35 F/89 12 % 3–5 % (11793–14289) Neg (121) Neg (134) Neg (102) Neg (102) Normal cytogenetics
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cutoff values associated with the greatest survival diffe-
rence for predicting poor clinical outcome [17].
A caveat of Target FISH was that although thousands or
ten thousands of cells were captured by the system on each
slide, the percentage categorized as plasma cells by the
machine before manual visualization and re-classification
was uneven and often discordant with the percentage deter-
mined by microscopic examination of the bone marrow
aspirate smears. Notably, a lower BioView percentage was
observed in 32 patients (80 %) in this cohort (Table 1). This
resulted in calling the FISH result based on less than the
target of at least 100 analyzable cells for each probe. This
scenario was seen consistently across all probes in only 5
patients. Further optimization of the density gradient
centrifugation and cytospin preparation were required to
prevent this apparent “cell loss” in the Target FISH experi-
ments. Following on this, Target FISH might not be appli-
cable to the study of MGUS in which the plasma cell
percentage was low, in contrast to cell sorting in which a
larger volume of bone marrow blood could be used if
available.
Before the implementation of Target FISH, plasma cell
enrichment was performed by cell sorting with CD138
immunomagnetic beads (Miltenyi Biotec GmbH, Germany)
on 253 patients and this cohort did not include the 40
patients for whom Target FISH was performed. The cohort
consisted of 161 male and 92 female patients at a median
age of 61 years (range: 38–88 years). The median bone
marrow plasma cell percentage was 42 % and cell sorting
was only performed in the 140 patients (55 %) with less
than 50 % plasma cells in the bone marrow. The purity
after cell sorting was checked by cytospin preparation. The
volume of bone marrow sample was 1–3 mLs and compa-
rable with Target FISH. Fluorescence microscopy was
performed by two observers who analyzed at least 100 cells
each. Positive cutoff levels of 10 % for fusions and 20 % for
numerical abnormalities were adopted for reporting. For
comparison with Target FISH, the frequency of cytogenetic
abnormalities was 41.9 % for +1q21, 16.6 % for t(4;14) IGH/
FGFR3, 0.9 % for t(14;16) IGH/MAF and 7.5 % for
del(17p)/TP53.
The workflow and cost of Target FISH was compared
with cell sorting by immunomagnetic beads (Table 2).
Unfortunately our laboratory had no experience with cIg-
FISH which precluded any comparison. The Target FISH
was a 3-day procedure but for urgent cases the first 2 days
could be combined into one day to stop at the probe
hybridization step overnight to obtain the FISH results the
next day. The total reagent cost of Target FISH was
around 10 % less expensive than cell sorting because there
was no need to employ the immunomagnetic beads. The
equipment cost however had to be taken into conside-
ration. The total processing time of Target FISH however
was longer than cell sorting. This notwithstanding, the 3 h
(4 slides at 45 min each) of BioView slide scanning on day
3 were performed automatically by the machine after the
cell matching was verified, instead of the tedious 2-h
manual examination under fluorescence microscopy in
the dark room. Moreover, the reporting procedure was
facilitated since all the captured images could be reviewed
on the computer monitor. Under manual examination only
the representative images were captured and one would
resort to repeat fluorescence microscopy for countercheck-
ing results. The manpower requirement was equivalent for
both Target FISH and cell sorting.
Conclusion
Correlation of plasma cell morphology with FISH by
manual means [18] was not a new concept. Neither was
automated image analysis an entirely new concept for the
purpose of plasma cell identification in myeloma FISH
[19]. Consistent with a previous report in the literature
[7], the Target FISH system presented in our study was
capable of combining the two processes in a fully
Table 1 Summary of Target FISH results on 40 patients (Continued)
36 F/50 56 % 14–17 % (10614–13489) Neg (140) Neg (143) Neg (111) 60 % + (137)
37 M/60 50 % 24–27 % (10633–13622) Neg (165) Neg (121) Neg (117) 83 % + (143)
38 M/79 20 % 6–10 % (13896–15969) Neg (125) Neg (96) Neg (121)g 80 % + (144) 80 % trisomy TP53
39 F/67 53 % 32–38 % (13807–17047) Neg (162) 63 % + (123) Neg (103) 63 % + (104)
40 M/69 57 % 6–13 % (12778–15272) Neg (158) Neg (127) Neg (148) Neg (158)
Key:
aThe PC% refers to the plasma cell percentage in the bone marrow aspirate as enumerated on microscopic examination
bThe BioView data refers to the percentage of cells in the plasma cell category as recognized by the automated image capture and analysis system before manual
re-classification. The number in the parentheses refers to the total number of cells analyzed by the automated image capture and analysis system on
the slide. Both are reported as a range of figures obtained from the 4 slides
cThe number in parenthesis is the actual number of re-classified plasma cells with optimal FISH signals on which the positive or negative result is based.
This figure is also indicated on the pathology report for each FISH probe
d26 ~ 45,XX,t(4;14)(p16;q32)[33]/48 ~ 159,XX[3]/46,XX[6]
e43 ~ 44,XY,+3[2],der(4)t(1;4)(q21;p16)[2],add(7)(p13)[2],+7 ~ 8mar[2][cp2]/46,XY[4]
f45,X,-Y[3]/46,XY[15]
gDenotes the incidental finding of secondary abnormalities i.e. monosomy of deletion of chromosomes 4, 14 or 16; trisomy or amplification of chromosomes 4, 14 or 16
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automated fashion for relocation of plasma cells to allow
the analysis of the MGG image and FISH signals of the
same plasma cell. In this way, it was 100 % ensured that
the cytogenetic abnormality - if any was detected - was
found in the cells of interest. Target FISH saved the cost
on reagent, obviated the need for tedious manual fluores-
cence microscopy and enriched the sample to completely
focus on the analysis of plasma cells. We reckoned that
Target FISH was applicable as an attractive alternative to
cell sorting and cIg-FISH as a method of plasma cell
enrichment for detection of PCM cytogenetic abnorma-
lities in clinical molecular diagnostic laboratories.
Methods
Bone marrow preparation for morphology
Mononuclear cells in the bone marrow were separated by
density gradient centrifugation to prepare cytospin slides
for staining and morphological examination by BioView
system (Abbott Molecular, Des Plaines, IL). Around 2 mL
of bone marrow blood in EDTA was processed. Briefly,
bone marrow was diluted 1:4 with wash buffer and added
slowly to separation reagent prepared from 1 volume of
Histopaque 1.077 (Sigma) mixed with 3 volumes of Histo-
paque 1.119. The mixture was centrifuged at 500 g for
30 min and decelerated slowly for 30 min to zero. Care
was taken not to disturb the different layer when remo-
ving the tube from the centrifuge. The mononuclear cell
layer at the interface between the plasma layer above and
the Ficoll-hypaque layer below was carefully pipetted off
to another tube and washed twice. The cell pellet was
re-suspended in morphology preserver consisting of
Fetal Bovine Serum in Ham’s F-10 Nutrient Mix (Life
Technologies).
Preparation of cytospin slides and MGG Staining
The cytospin centrifuge produced single-layer cell prepa-
rations that also flattened the cells for optimal cytoplasmic
and nuclear presentation required for morphology ana-
lysis. 10–20 mLs of cell pellet were added to 2–3 mLs of
Morphology Preserver to create the cell suspension. Up to
200 μLs of this suspension was loaded to a cuvette and
centrifuged at 1500 rpm for 5 min. The slide was then
carefully extracted from the cuvette and allowed to dry
after marking the area around the cells. The cell density
was checked under light microscopy by a 20x dry objec-
tive to ensure single layer of cells that showed minimal
cellular overlap and no clustering. High concentration
caused the cells to overlap hence difficult to scan and
classify, and low concentration reduced the analyzable cell
number that adversely affected the test result. The con-
centration of the suspension should be adjusted by dilu-
tion or addition of more cell pellet as deemed necessary.
At least 8 cytospin slides were made, 4 for the 4-probe
myeloma FISH panel used in our laboratory and 4 for
backup. Slides could be stored at −20 °C for up to
2 months until staining.
The cytospin slides were stained successively in May-
Grünwald stain for 2 min and in 5 % Giemsa stain for
8 min. After drying, the slides were checked under light
microscopy to confirm the appropriate staining quality for
BioView scanning. Freshly prepared MGG stains were
prepared each time to ensure optimal staining quality for
plasma cell image recognition by BioView.
Automated scanning of the MGG-stained slides by
BioView
The slide was loaded onto the stage of BioView for scan-
ning and time required was around 15–20 min per slide
Table 2 Comparison between cell soring by immunomagnetic beads and Target FISH









Day 1 Plasma cell sorting by MACS whole
blood CD138 μ-beads
1.5 60 Day 1 Plasma cell enrichment by Ficoll 1.5 12
Cytospin slides (10 slides per sample) 0.5 29
Cytospin slides (10 slides per sample) 0.5 29 MGG staining 0.5 9
BioView scan and review 2.0 0
Day 2 Lysis of red blood cells on slide 0.5 2 Day 2 De-staining of MGG 1.5 2
FISH hybridization 3.0 236 FISH hybridization 3.0 236
Probe hybridization Overnight 0 Probe hybridization Overnight 0
Day 3 Post-hybridization 1.0 13 Day 3 Post-hybridization 1.0 13
Manual slide examination 2.0 0 BioView slide scan 3–4 0
Review results, data analysis and
reporting
2.0 0 Review results, data analysis
and reporting
2.0 0
Total 10.5 340 Total 15–16 301
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depending on the cell quantity. After scanning, the plasma
cell category as automatically selected by the machine was
reviewed and bona fide plasma cells were reclassified into
‘my_class’ (Fig. 1). The aim was to obtain 200 plasma cells
per slide for FISH to allow for hybridization failure since
the reporting target was at least 100 plasma cells with clear
FISH signals. If insufficient plasma cells were obtained,
other categories were reviewed to move plasma cells into
‘my_class’ category.
MGG de-staining and interphase FISH procedure
De-staining was performed by immersing slide in ice-cold
(−20 °C) Carnoy’s solution (methanol: acetic acid 3:1) for
2 min at room temperature, and then moved to be
immersed in another jar for 1 h. The slide was rinsed in 1x
phosphate buffered saline for 5 min to be ready for FISH.
The pre-hybridization, probe hybridization and post-
hybridization procedures were performed in accordance
with standard leukemia lymphoma FISH protocols
[20, 21]. Four FISH probes constituted the myeloma
panel in our laboratory based on recommendations of the
International Myeloma Working Group [1, 3, 22], namely
Vysis TP53/CEP17 FISH probe kit (5 N56-20), Vysis IGH/
FGFR3 DF FISH probe kit (1 N69-20), Vysis IGH/MAF
DF FISH probe kit (5 N32-20) from Abbott Molecular,
and CKS1B/CDKN2C(P18) Amplification/Deletion probe
kit (LPH 039) from Cytocell (Cambridge, UK). Other
FISH probes such as cyclin D1 gene amplification [23]
were not routinely applied. However the IGH/CCND1
probe would be used when t(11;14) myeloma was sus-
pected. Probe hybridization was performed on either Vysis
HYBrite or ThermoBrite (Abbott Molecular).
Fig. 1 a From 5333 cells that were captured on this particular MGG stained slide, the image capture and analysis system automatically assigned
1301 cells to the plasma cell category. b The plasma cell category was manually reviewed to reclassify bona fide or clearly abnormal plasma cells
into My_class category, which contained 200 cells in this case
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Scanning FISH slides by BioView
The slides were mounted on the stage and immersion oil
was applied manually. Through the computer terminal, the
corresponding case and slide number were documented,
and the appropriate scanning task and probe name were se-
lected. The images of the MGG-stained plasma cells were
retrieved from the ‘re-visit my_class’ of the scan program
and a dual-view screen was opened, in which a live image
of the slide under fluorescence microscopy was displayed
on the left side and the bright field image of the plasma
cells on the right side, thus allowing direct matching of the
FISH signal and morphology. The BioView captured images
from 13 focal planes spaced 0.65 μm apart for each cell to
minimize chance juxtaposition of FISH signals as a cause of
false positive fusion signal pattern. Once a relocated plasma
cell with clear FISH signals was identified from the live
image, the bright field image previous captured was
checked for accuracy of localization based on size, shape
and surrounding cells. If a match was verified, both images
were centered and the process was finished for that parti-
cular plasma cell. The process was then repeated for as
many cells on whatever number of slides as required by the
laboratory. We aimed to select at least 100 cells per slide
with clear FISH signals, and 4 slides were used per patient
for a myeloma panel of 4 probes. When all the slides for
the case were properly configured, the slides were scanned
automatically at around 45 min per slide.
When scanning was completed, the results were manu-
ally visualized from the BioView software. A statistically
summary of the FISH signal patterns of the selected
plasma cells of each particular probe was displayed. More-
over, a composite image of FISH on the left side and
MGG-stained picture of the same plasma cell on the right
side could be prepared for inclusion in the pathology
report (Fig. 2).
Abbreviations
FISH, fluorescence in-situ hybridization; MACS, magnetic-activated cell
sorting; MGG, May-Grünwald-Giemsa; PCM, plasma cell myeloma;
SD, standard deviation
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Fig. 2 Images of MGG stained (right) and FISH probe hybridized (left) plasma cells. a t(4;14) IGH/FGFR3 probe, showing the 2F1O1G signal pattern
on a positive plasma cell. b t(14;16) IGH/MAF probe, showing the 2O2G signal pattern on a negative plasma cell. c CKS1B/CDKN2C(P18) probe,
showing 3O2G signal pattern on the plasma cell positive for +1q21. d TP53/CEP17 probe, showing 1O2G signal pattern on the plasma cell
positive for del(17p)/TP53
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